IRD Opus Genetics, Inc.
$6.04▼ -0.49%
Healthcare
Other
After hours
$6.02▼ -0.33%
Sep 11, 7:58 PM ET
Volume 4.65M
Avg Volume (10D) 7.76M
Key Metrics & Fundamentals
Market Cap
$502.50M
P/E Ratio
–
Div Yield
–%
52W Range
1.35 - 7.07
% vs 50 MA
57.73%
% vs 200 MA
61.96%
RSI-14
77.6
MACD Histogram
+0.2100
Beta (1Y vs SPY)
1.10
Free Cash Flow
-$11.95M
Gross Rev
$755,000
Gross Profit
$755,000
EBITDA
-$14.73M
COGS
–
Operating Exp
$17.24M
Operating Income
-$16.48M
EBIT
-$16.48M
Pretax Income
-$8.10M
Net Income
-$8.10M
EPS (Diluted)
-0.08
Price & Volume History
Loading chart…
Recent News
Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating
MT Newswires · Sep 10, 2026 11:43 AM
Correction: Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating
MT Newswires · Sep 10, 2026 11:40 AM
Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating
MT Newswires · Sep 10, 2026 11:24 AM
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · Sep 9, 2026 7:49 PM
Update: Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial
MT Newswires · Sep 9, 2026 6:35 PM
Top Midday Gainers
MT Newswires · Sep 9, 2026 6:05 PM
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
Stocktwits · Sep 9, 2026 5:19 PM
Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating
MT Newswires · Sep 9, 2026 4:34 PM
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027
InvestorsHub · Sep 9, 2026 2:37 PM
BC-Most Active Stocks
Associated Press · Sep 9, 2026 2:30 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See IRD's money flow as a full page
Social Sentiment
No Reddit posts found for IRD.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.